Tags

Type your tag names separated by a space and hit enter

Migraine and Tension-Type Headache.
Semin Neurol. 2018 12; 38(6):608-618.SN

Abstract

Migraine and tension-type headache (TTH) are common primary disorders that carry significant morbidity and socioeconomic effect. In this article, we will review the epidemiology, presentation, and diagnosis of these disorders. First-line acute treatment for migraine consists of analgesics, triptans, and antiemetics, while nonsteroidal anti-inflammatory drugs are the mainstay treatment for TTH. Patients with frequent or chronic headaches warrant prophylactic therapy. For migraine, various classes of preventives can be used (β-blockers, tricyclics, antiepileptics, botulinum toxin), with the choice of therapy tailored to the patient's risk factors and symptoms. For TTH, tricyclics have the most evidence as prophylactic therapy. A new class of medication, monoclonal antibodies to calcitonin gene receptor peptide or its receptor, became available in 2018, and is the first class of medication specifically designed to treat migraine. In addition to pharmacotherapy, we will also review nonpharmacologic interventions as well as neuromodulation for migraine.

Authors+Show Affiliations

Department of Neurology, Boston Medical Center, Boston, Massachusetts.Department of Neurology, Boston Medical Center, Boston, Massachusetts.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

30522135

Citation

Kahriman, Azmin, and Shuhan Zhu. "Migraine and Tension-Type Headache." Seminars in Neurology, vol. 38, no. 6, 2018, pp. 608-618.
Kahriman A, Zhu S. Migraine and Tension-Type Headache. Semin Neurol. 2018;38(6):608-618.
Kahriman, A., & Zhu, S. (2018). Migraine and Tension-Type Headache. Seminars in Neurology, 38(6), 608-618. https://doi.org/10.1055/s-0038-1673683
Kahriman A, Zhu S. Migraine and Tension-Type Headache. Semin Neurol. 2018;38(6):608-618. PubMed PMID: 30522135.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Migraine and Tension-Type Headache. AU - Kahriman,Azmin, AU - Zhu,Shuhan, Y1 - 2018/12/06/ PY - 2018/12/7/entrez PY - 2018/12/7/pubmed PY - 2019/3/16/medline SP - 608 EP - 618 JF - Seminars in neurology JO - Semin Neurol VL - 38 IS - 6 N2 - Migraine and tension-type headache (TTH) are common primary disorders that carry significant morbidity and socioeconomic effect. In this article, we will review the epidemiology, presentation, and diagnosis of these disorders. First-line acute treatment for migraine consists of analgesics, triptans, and antiemetics, while nonsteroidal anti-inflammatory drugs are the mainstay treatment for TTH. Patients with frequent or chronic headaches warrant prophylactic therapy. For migraine, various classes of preventives can be used (β-blockers, tricyclics, antiepileptics, botulinum toxin), with the choice of therapy tailored to the patient's risk factors and symptoms. For TTH, tricyclics have the most evidence as prophylactic therapy. A new class of medication, monoclonal antibodies to calcitonin gene receptor peptide or its receptor, became available in 2018, and is the first class of medication specifically designed to treat migraine. In addition to pharmacotherapy, we will also review nonpharmacologic interventions as well as neuromodulation for migraine. SN - 1098-9021 UR - https://www.unboundmedicine.com/medline/citation/30522135/Migraine_and_Tension_Type_Headache_ DB - PRIME DP - Unbound Medicine ER -